学术探索
学术期刊
新闻热点
数据分析
智能评审

How well does the evidence on pioglitazone back up researchers' claims for a reduction in macrovascular events?

被引：27
作者：
Freemantle, N [1 ]
机构：
[1] Univ Birmingham, Birmingham B15 2TT, W Midlands, England
来源：
BRITISH MEDICAL JOURNAL | 2005年 / 331卷 / 7520期
关键词：
D O I：
10.1136/bmj.331.7520.836
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：836 / 838
页数：3
相关论文
共 3 条
[1]   Carvedilol and the food and drug administration (FDA) approval process: The FDA paradigm and reflections on hypothesis testing [J].
Fisher, LD .
CONTROLLED CLINICAL TRIALS, 1999, 20 (01) :16-39
[2]   Composite outcomes in randomized trials - Greater precision but with greater uncertainty? [J].
Freemantle, N ;
Calvert, M ;
Wood, J ;
Eastaugh, J ;
Griffin, C .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2003, 289 (19) :2554-2559
[3]   Interpreting the results of secondary end points and subgroup analyses in clinical trials: should we lock the crazy aunt in the attic? [J].
Freemantle, N .
BRITISH MEDICAL JOURNAL, 2001, 322 (7292) :989-991
1